Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$21.20M$21.20Mderived+1.0% vs Q4 2022 Net Income$114.00K$114.00KderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$12,937,000+7.7% Operating Incomederived-$168,000N/M Operating Cash Flowderived$649,000N/M Margins · derivedGross margin61.0%+3.8 pt vs Q4 2022
Operating margin-0.8%+6.1 pt vs Q4 2022
Net margin0.5%+7.3 pt vs Q4 2022
ended Dec 31, 2023 · filed Mar 6, 2024 · 66 d after period end